Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senl-T7 CAR-T in Relapsed/Refractory CD7+ Lymphoma
NCT04928105Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENL101 in T-cell lymphoma, sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month, Remission Rate at 3 months and 4 more. Status: unknown.
02
Drugs
SENL101
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT04928105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928105.